Pharma Start, Acino Group
The Bravery Award honors companies that fearlessly navigate the turbulent waters of wartime in Ukraine. We are proud of your resilience, remarkable adaptability, and commitment to conducting business in Ukraine.
Pharma Start is a manufacturing plant of the Swiss pharmaceutical company Acino, founded in 1836 and specializing today in the development, production and promotion of high-quality drugs in the pharmaceutical market. The company is owned by the holding company ADQ. Headquarters is in Zurich. The company focuses on selected markets in the Middle East, Africa, the CIS and Latin America. As a global partner of pharmaceutical companies, Acino provides turnkey solutions from drug development and registration to contract manufacturing, packaging and logistics.
Acino has been operating in Ukraine since 2015 after the acquisition of Pharma Start and today ranks second in the domestic pharmaceutical market, providing hundreds of millions in budget revenues.
Acino’s office in Ukraine is located in Kyiv and serves as the regional headquarters for Acino’s business in the CIS. Acino in Ukraine focuses its activities in the following areas:
- development and production of effective, safe and high-quality generic drugs and dietary supplements;
- commercial sale and promotion of medicines of international pharmaceutical companies on the territory of Ukraine and in the CIS countries;
- contract manufacturing and licensing to promote partners.
The Pharma Start plant is located in Kyiv, certified in accordance with the standards of GMP EU and equipped with a R&D laboratory for the development of generic drugs, which produces 2-3 new products and improves 10-12 products in the active portfolio annually. The plant is equipped with modern high-tech equipment from world leaders with a production capacity of 1 billion capsules and 1 billion solid dosage forms per year. Exports to 7 CIS countries and South-West Asia. The volume of investments in the development of the plant during 2015-2021 amounted to 26.5 million euros.
Acino’s portfolio of drugs, dietary supplements and medicines in Ukraine includes more than 80 products both in-house and distribution agreements, used in neurology, cardiology, endocrinology, gastroenterology, pediatrics and therapy.
Today, Acino in Ukraine has more than 900 highly qualified employees, including more than 100 specialists who work as the Hub service functions that provide Acino operations in approximately 90 countries around the world.
The company’s mission is to develop, manufacture and commercialize high quality pharmaceuticals for benefit of patients.
At the beginning of the war, Acino donated 75,000 packages of vital drugs and provided welfare aid in the amount of UAH 20 million to humanitarian causes.